Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules

被引:18
作者
Cross, LJ
Bagg, J
Oliver, D
Warnock, D
机构
[1] Univ Glasgow, Sch Dent, Glasgow G2 3JZ, Lanark, Scotland
[2] Publ Hlth Lab Serv, Mycol Reference Lab, Bristol, Avon, England
关键词
D O I
10.1093/jac/45.1.95
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to compare the concentrations of itraconazole in serum and saliva after treatment with itraconazole cyclodextrin solution or itraconazole capsules in Candida-associated denture stomatitis patients without evidence of immunodeficiency. Forty patients were randomly assigned to receive either itraconazole cyclodextrin solution or itraconazole capsules, both at a dosage of 100 mg bd for 15 days. On completion of treatment palatal erythema was assessed and an oral rinse and imprint cultures were collected. Serum and saliva samples were collected at the same time and itraconazole concentrations measured using reverse-phase high-performance liquid chromatography. Itraconazole susceptibilities of Candida albicans and Candida glabrata strains isolated at baseline were measured by a broth microdilution method. Serum itraconazole concentrations achieved did not differ significantly between the two preparations (P = 0.39) although a significantly higher number of patients in the itraconazole cyclodextrin group (P < 0.001) had detectable levels of itraconazole in their saliva compared with the capsule group. Mycologically cured patients had slightly, though not significantly (P = 0.28), higher serum itraconazole concentrations than those from whom yeasts were not eradicated. It was concluded that both formulations of itraconazole were equally effective in treatment of denture stomatitis. Among immunocompetent patients, the absorption of the liquid preparation is no greater than that of the capsules. Therapeutic success in this group was achieved with lower serum itraconazole concentrations than have been reported for immunocompromised groups.
引用
收藏
页码:95 / 99
页数:5
相关论文
共 10 条
[1]  
*BRIT MED ASS ROYA, 1996, BRIT NATL FORMULARY, V32, P262
[2]  
Budtz-Jorgensen E., 1990, Oral candidosis., P156
[3]  
BUDTZJORGENSEN E, 1974, SCAND J DENT RES, V82, P151
[4]   EPIDEMIOLOGIC STUDY OF YEASTS IN ELDERLY DENTURE WEARERS [J].
BUDTZJORGENSEN, E ;
STENDERUP, A ;
GRABOWSKI, M .
COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY, 1975, 3 (03) :115-119
[5]   Itraconazole solution: Higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis [J].
Cartledge, JD ;
Midgely, J ;
Gazzard, BG .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (06) :477-480
[6]   ITRACONAZOLE CYCLODEXTRIN SOLUTION - EFFECTIVE TREATMENT FOR HIV-RELATED CANDIDOSIS UNRESPONSIVE TO OTHER AZOLE THERAPY [J].
CARTLEDGE, JD ;
MIDGLEY, J ;
YOULE, M ;
GAZZARD, BG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (05) :1071-1073
[7]  
Cross LJ, 1998, J ORAL REHABIL, V25, P496
[8]  
*JANSS CIL LTD, 1996, SPOR ITR SYST FUNG I, P75
[9]   Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections [J].
Rex, JH ;
Pfaller, MA ;
Galgiani, JN ;
Bartlett, MS ;
EspinelIngroff, A ;
Ghannoum, MA ;
Lancaster, M ;
Odds, FC ;
Rinaldi, MG ;
Walsh, TJ ;
Barry, AL .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :235-247
[10]   COMPARISON OF HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC AND MICROBIOLOGICAL METHODS FOR DETERMINATION OF ITRACONAZOLE [J].
WARNOCK, DW ;
TURNER, A ;
BURKE, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 21 (01) :93-100